Mycobacterium tuberculosis Biofilms: Immune Responses, Role in TB Pathology, and Potential Treatment.
Muluneh AssefaTadesse AtanawPublished in: ImmunoTargets and therapy (2024)
Tuberculosis (TB) is a major public health problem worldwide, and the burden of drug-resistant TB is rapidly increasing. Although there are literatures about the Mtb biofilms, their impact on immune responses has not yet been summarized. This review article provides recent knowledge on Mycobacterium tuberculosis ( Mtb ) biofilm-immunity interactions, their importance in pulmonary TB pathology, and immune-based therapy targeting Mtb biofilms. Pellicle/biofilm formation in Mtb contributes to drug resistance, persistence, chronicity, surface attachment, transfer of resistance genes, and modulation of the immune response, including reduced complement activation, changes in the expression of antigenic proteins, enhanced activation of T-lymphocytes, elevated local IFNγ+ T cells, and strong antibody production. The combination of anti-TB drugs and anti-biofilm agents has recently become an effective strategy to improve TB treatment. Additionally, immune-targeted therapy and biofilm-based vaccines are crucial for TB prevention.
Keyphrases
- mycobacterium tuberculosis
- immune response
- candida albicans
- biofilm formation
- pulmonary tuberculosis
- pseudomonas aeruginosa
- drug resistant
- staphylococcus aureus
- public health
- multidrug resistant
- dendritic cells
- healthcare
- toll like receptor
- escherichia coli
- poor prognosis
- genome wide
- stem cells
- mesenchymal stem cells
- climate change
- risk factors
- human immunodeficiency virus
- human health
- gene expression
- drug delivery
- risk assessment
- hiv aids